about
A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trialInactivated whole virus influenza A (H5N1) vaccineConservation of the Caenorhabditis elegans timing gene clk-1 from yeast to human: a gene required for ubiquinone biosynthesis with potential implications for agingInfluenza A (H5N1) pandemic prototype vaccine Fluval.New oral anticoagulants in the treatment of heparin-induced thrombocytopenia.Echocardiographic findings in patients with Williams-Beuren syndrome.Pulseless electrical activity in pulmonary embolism treated with thrombolysis (from the "PEAPETT" study).Transforming and simplifying the treatment of pulmonary embolism: "safe dose" thrombolysis plus new oral anticoagulants.Facial and dental appearance of Williams syndrome.Complex care by multiple medical and dental specialists of a patient with aggressive Gorlin-Goltz syndrome.Managing lipid disorders: further evaluation of the VA-HIT.Effect of simvastatin on endothelial function in cardiac syndrome X patients.Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension.The role of dental evaluation and cephalometric analysis in the diagnosis of Williams-Beuren syndrome.Picture of the month. Klippel-Trenaunay syndrome.Impaired beta 2-adrenergic agonist-induced venodilation in Indians of Asian originElevated endothelin-1 levels and persistent stage IV hypertension in a nonvolume overloaded anephric patientProstacyclin and thromboxane production of rat and cat arterial tissue is altered independently by several vasoactive substancesPostmenopausal hormone replacement therapy and cardiovascular mortality in Central-Eastern EuropeIncreased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal womenParadoxically enhanced bradykinin-induced venodilation in young, healthy, short-term smokersThe seasonal influenza vaccine Agriflu(®)
P50
Q24623902-1279F229-B4E9-418B-884F-4BF7CEC7E780Q24658394-2F2990D8-B94E-4729-B8FD-9A06F1AFA694Q28638181-09237B24-5B00-41C5-817A-B92A3635832FQ30376553-F8B306F0-EFFD-429B-9C01-7DD9EA3C220AQ33419946-E313D249-D2BF-44A5-9E57-FCA0D38F2AEAQ34569940-603FC168-7EFA-4EB4-B290-0D4D7D17A87FQ39597118-8197DEBB-CFF0-447E-8C17-95D8112C882FQ41271973-9E2A620B-2587-46A3-9FE7-407BCA50007AQ42056598-15274311-133F-45A6-95AB-3D53C00A0121Q42439254-F53CD909-DAAF-4E72-A0DA-DCB85CD6A432Q44450955-264015D7-F941-4F52-BCF6-E8CE12864797Q45040784-1E4BEEC7-A198-41F5-8328-00B63E46D49EQ51554179-E432B276-4B0C-4696-A889-0C18D7C65CAEQ52050649-8C7BC4E4-3743-4B4E-AD0F-31B3ABC4B8F8Q52182385-B4B8DCA1-5475-4870-BF82-8C3D7D314BFCQ71117308-648A5B9D-E6F5-4F86-AD67-D1B121B725C9Q71702210-4B01318B-4404-4E1D-9ADF-0C4C9A3AA3D3Q71759563-C6ABD380-2351-4F9E-95EC-1133650F4E77Q73745021-A4C8C946-6EA3-42FB-ACCD-832EBDE56F98Q77647860-656BF611-9CBF-4848-8F45-1789503419A0Q78120886-1054768C-82F3-4C99-B527-90587CB0CF21Q82291006-0C537216-DE93-4595-B367-423EE90F0A93
P50
description
researcher
@en
wetenschapper
@nl
name
Vajo Z
@nl
Zoltan Vajo
@en
type
label
Vajo Z
@nl
Zoltan Vajo
@en
altLabel
Vajo Z
@en
prefLabel
Vajo Z
@nl
Zoltan Vajo
@en
P106
P31
P496
0000-0003-1049-1694